NFE2L2 and cancer: This regulation of HER4 expression by NRF2 appeared to be modulated by LAP or ERL drug, which may also be a contributing determinant and basis of cellular sensitivity and response (susceptibility and resistance) of some cancers to LAP and/or ERL.